3 results
Approved WMOPending
The Primary objective is to assess the long-term (6 month and 12 month) safety of the combination of aliskiren 300 mg/ valsartan 320 mg in patients with essential hypertension (msDBP > 90 mmHg and < 110 mmHg.
Approved WMOPending
To investigate the long-term safety, tolerability and acceptability of Nasalfent in the treatment BTCP
Approved WMOCompleted
Examining the applicability of a fieldable serological point of care serological test Biozek and Point of care molecular Fluorescent in Situ Hybridization (FISH) technology by Biotrack for the usage of decision making, containment and management of…